Alnylam Focuses on Two Lead Programs, Won't Advance Others without Partners | GenomeWeb

By Doug Macron

Alnylam Pharmaceuticals this week re-organized its pipeline to focus on its drug-development programs in transthyretin-mediated amyloidosis and hemophilia, opting to advance its other programs only through partnerships.

"As we effect our transformation from a platform company to a product company, now is the time to focus our near-term efforts on what we believe to be our highest value opportunities with accelerated clinical development plans,” Alnylam CEO John Maraganore said in a statement.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

Replication studies that don't quite reflect the original findings underscore the need to better share data, the Wall Street Journal reports.

About two-thirds of proposals to work with select agents are denied — though most proposals that come in don't meet the definition of a restricted experiment, according to an analysis by the Centers for Disease Control and Prevention.

Researchers examine plant and human DNA found on the Shroud of Turin.

In PNAS this week: Plasmodium knowlesi population structure, 'pre-adaptations' in algal ancestors of land plants, and more.